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Abstract: The hypoxia signalling pathway enables adaptation of cells to decreased oxygen 15 
availability. When oxygen becomes limiting, the central transcription factors of the pathway, 16 
hypoxia-inducible factors (HIFs), are stabilised and activated to induce the expression of hypoxia-17 
regulated genes, thereby maintaining cellular homeostasis. Whilst hydroxylation has been 18 
thoroughly described as the major and canonical modification of the HIF-α subunits, regulating 19 
both HIF stability and activity, a range of other post-translational modifications decorating the 20 
entire protein play also a crucial role in altering HIF localisation, stability, and activity. These 21 
modifications, their conservation throughout evolution and their effects on HIF-dependent 22 
signalling are discussed in this review. 23 
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1. Introduction 28 
Many pathways in mammalian cells rely on molecular oxygen; especially during the final step 29 
of the mitochondrial respiratory chain. If oxygen levels drop below a cell-dependent critical level, 30 
cells experience hypoxia and cannot sustain aerobic respiration and subsequent ATP production. A 31 
switch to glycolysis, the less efficient but oxygen-independent pathway of producing ATP, is 32 
required to ensure cell survival. The sensing of cellular oxygen levels, the associated switch between 33 
modes of energy generation and ultimately the adaption to a low oxygen environment, is controlled 34 
by the hypoxia signalling pathway. Hypoxia-inducible factors (HIFs), of which the first was described 35 
as a nuclear factor that enhances transcription of the erythropoietin (EPO) gene under hypoxic 36 
conditions by binding to a 3' enhancer sequence element, are part of this pathway and maintain the 37 
adaptation at the transcriptional level [1,2]. HIFs consists of an oxygen-dependent α subunit that is 38 
destabilised in normoxia and a constitutively expressed β subunit (HIF-1β or ARNT) [3,4]. Three HIF-39 
α subunits (HIF-1α, HIF-2α, HIF-3α) have been described, of which HIF-1α and HIF-2α are the best 40 
understood and considered as the major activators of hypoxia-induced gene transcription [2,5,6]. 41 
HIF-α and HIF-1β heterodimerise via their basic helix-loop-helix (bHLH)/Per-ARNT-Sim (PAS) 42 
domains to form the active transcription factor dimer, which then binds to hypoxia response elements 43 
(HREs) within the DNA of target genes [7]. HIFs then recruit general co-activators such as CBP/p300 44 
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via the C-terminal transactivation domain (C-TAD), leading to the expression of more than ~300 45 
genes [8,9].  46 
While HIF-1α and HIF-2α appear to be able to bind the same HRE, they can occupy distinct 47 
genomic sites, which vary with cell types. They display different subnuclear localisation and 48 
intranuclear diffusion speed [10]. In addition, some studies showed that neither HIF-1α nor HIF-2α 49 
could substitute the lack of DNA binding caused by the absence of the one or the other HIF-α variant 50 
[11]. However, others have shown that the loss of a single HIF‐α isoform (either HIF‐1α or HIF‐2α) 51 
is compensated by the enhanced expression of the other and promote survival during cancer 52 
development [12]. This highlights the potential for specific contexts, whereby there may be a 53 
compensation mechanism when a single HIF-α isoform is silenced.These findings support in part, 54 
the idea that HIF-1α accounts for acute and HIF-2α for chronic responses to hypoxia [13]. HIF-3α is 55 
less explored than HIF-1α or HIF-2α. HIF-3α mRNA is subject to alternative splicing in humans and 56 
in mice [14,15]. A specific mouse splice variant called inhibitory PAS domain protein (IPAS) was 57 
shown to interact directly with HIF-1α. The IPAS/HIF-1α complex was unable to bind to HREs and 58 
suggested to be a negative regulator of HIF-1α [16,17]. By contrast, the long human splice variant 59 
HIF-3α2 induces expression of various genes among them the EPO gene [18].  60 
The canonical regulation of HIF-α protein stability and activity involves a series of molecular 61 
interactions and reversible covalent modifications to specific amino acids, termed post-translational 62 
modifications (PTMs) [19-21]. A PTM can alter a protein's enzymatic activity, localisation, stability, 63 
and/or interaction with other proteins. Therefore, these non-genetically encoded modifications that 64 
are mainly carried out by enzymes, add to the complexity of the proteome as they can ascribe 65 
different functionalities to the same gene product. Common PTMs to a target protein include 66 
phosphorylation, acetylation, methylation, and alkylation as well as the covalent linkage of fatty 67 
acids, saccharides or small proteins such as ubiquitin and SUMO (small ubiquitin-related modifier) 68 
[22]. This review examines and discusses the current PTM landscape of HIF-α and their respective 69 
functional consequences on HIFs. 70 
2. Canonical regulation of HIF-α, the role of ubiquitination 71 
Whilst regulation of HIF mRNA levels by hypoxia plays a minor role in HIF abundance, 72 
regulation of protein stability, via PTMs, is essential for appropriate HIF accumulation during 73 
hypoxia [23]. The HIF-α proteins are destabilised in normoxia via the ubiquitin-proteasome pathway 74 
(Figure 1) [24,25]. To achieve this, post-translational hydroxylation of two conserved proline residues 75 
(Pro-402/Pro-564 in HIF-1α; Pro-405/ Pro-531 in HIF-2α; P492 in HIF-3α) residing within an oxygen-76 
dependent-degradation (ODD) domain is required [19,20,26,27]. Prolyl hydroxylation is carried out 77 
by three mammalian HIF prolyl hydroxylases (PHD1, -2, and -3; also known as EglN2, EglN1, and 78 
EglN3, respectively). PHD2 acts as the main regulator of HIF-α degradation and has a key role in 79 
HIF-α intracellular dynamics [28,29]. Once hydroxylated, the HIF-α proteins are recognised by an 80 
E3-ligase complex containing the von-Hippel-Lindau protein (pVHL), which acts as the substrate 81 
recognition unit and, together with Cullin-2 (Cul-2), Elongin-1, Elongin-2 and Ring-Box 1 (RBX1), 82 
polyubiquitinates K532, K538 or K567 on HIF-1α (and K497, K503 or K512 on HIF-2α) [30-33]. The 83 
polyubiquitylated HIF-α proteins are then degraded via the 26S proteasome [19]. When cells are 84 
deprived of oxygen, PHDs have less molecular oxygen available to act as a co-factor, hence 85 
decreasing their activity and subsequent HIF-α hydroxylation [34]. Consequently, HIF-α subunits 86 
accumulate in the nucleus, form a heterodimer with the constitutively expressed HIF-1β and bind to 87 
HREs [7]. HIF-α hydroxylation is not exclusively mediated via PHDs, but also by the Factor-88 
Inhibiting HIF (FIH). FIH is an asparaginyl hydroxylase and modifies HIF-1α and HIF-2α on their C-89 
TAD residues N803 and N847, respectively [35,36]. During hypoxia, FIH activity is suppressed, 90 
allowing HIF-1α or -2α to complex with the CBP/p300 co-activators and increased transcriptional 91 
activation. HIF-α hydroxylation has long been considered to be an irreversible PTM, but it was 92 
recently shown, by mass spectrometry, that the FIH-mediated asparagine hydroxylation is indeed a 93 
reversible process [37].  94 
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Figure 1. The canonical oxygen-dependent degradation mechanism for HIF-α by pVHL-mediated 26S 95 
proteasomal degradation and its inhibition by FIH during hypoxia. 96 
Polyubiquitination is a quintessential PTM in preventing unwanted HIF-α accumulation in 97 
normoxia. Aside from ubiquitination, the action of deubiquitinating enzymes (termed DUBs) are 98 
well-known for their roles in regulating HIF-α. The action of DUBs on HIFs has been extensively and 99 
recently reviewed and will not be covered here [38,39].  100 
 101 
2. Non-canonical PTMs regulating HIF-α subunits 102 
Whilst there are many well-characterised binding partners and indirect regulators of HIF-1α and 103 
HIF-2α, PTMs constitute an essential direct regulatory mechanism for the HIF transcription factors 104 
[40]. PTMs abundantly decorate the full-length of these oxygen-sensitive proteins to exert specific 105 
regulatory forces. Most of these covalent modifications are enzymatically driven, with some 106 
exceptions such as S-nitrosylation. For the past two decades, the PTM landscape of HIF-1α and HIF-107 
2α has been ever-expanding, showing the intrinsic complexity and crosstalk of diverse intracellular 108 
signalling pathways implicating HIF activity, stability and localisation (Figure 2). 109 
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Figure 2. Localisation and function of non-canonical HIF-α PTMs mapped onto full-length HIF-1α 110 
(A) and HIF-2α (B). When a given PTM has multiple publications stating conflicting functional 111 
outcomes, then the functionality is denoted as 'controversial'. 112 
 113 
3. Phosphorylation 114 
Phosphorylation is an extremely common and well-studied PTM, involving the enzymatic 115 
addition of a phosphate group to serine, threonine, or tyrosine residues on a target protein 116 
(canonically within vertebrates). Moreover, a recent investigation highlighted the existence of 117 
additional 'non-canonical' phosphorylatable residues within human cells, including histidine, 118 
arginine, lysine, aspartate, glutamate and cysteine [41]. HIF-1α/HIF-2α modification by 119 
phosphorylation is abundant and has varied roles in regulating their stability, activity, subcellular 120 
localisation, and binding partner interactions (Figure 2). Whilst many of these direct phosphorylation 121 
events occur irrespective of oxygen tension, the modifications within the ODD domain appear to 122 
occur under normoxia exclusively.  123 
 124 
3.1 Phosphorylation by GSK-3β 125 
Glycogen Synthase Kinase-3 (GSK-3) is a serine/threonine kinase that was initially identified as 126 
a negative regulator of glycolysis. In mammals, two different isoforms have been identified: GSK-3α 127 
and GSK-3β, and despite their homology of 98% in their catalytical domain, their roles in metabolism 128 
are different [42-44]. Given that GSK-3 phosphorylates various upstream and downstream targets of 129 
the PI3K/AKT/mTOR signalling pathways, its activity is subject to tight regulation. Given the fact 130 
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that early hypoxia increased PKB/Akt activity as well as HIF-1α protein levels, it was shown that 131 
downregulation of GSK-3 enhanced HIF-1α, whereas overexpression of GSK-3β decreased HIF-1α 132 
protein levels, suggesting that HIF-1α is a direct target of GSK-3β [45,46]. Indeed, two independent 133 
investigations found distinct clusters of HIF-1α phosphorylation within its ODD domain and N-TAD, 134 
directly deposited by GSK-3β. One study identified S551, T555 and S589 as GSK-3β target sites based 135 
on kinase assays and experiments in hepatoma cells, while another study reported T498, S502, S505, 136 
T506 and S510 as GSK-3β sites in ovarian cancer cells [45,47]. Whilst this implies cell type specific 137 
aspects in the action of GSK-3, in both cases phosphorylation of HIF-1α by GSK-3β mediated the 138 
FBW7-E3 ubiquitin ligase-directed proteasomal degradation. This could be antagonised by the DUB 139 
ubiquitin-specific protease 28 (USP28) [47,48]. Interestingly, USP28 was found to be subject of a HIF-140 
regulated positive feedback loop. Therein, the USP28-inactivating sumoylation of USP28 at K99 141 
occurring under normoxia is reversed by direct interaction with SENP1 [49]. SENP1 itself is a 142 
transcriptional target of HIF-1. Hence, induced expression of SENP1 under hypoxia promotes 143 
desumoylation and activation of USP28, which then can contribute to further stabilisation of HIFs by 144 
their deubiquitynation activity (Figure 3). Taken together, this suggests that GSK-3β/USP28/SENP1 145 
are highly coordinated to maintain an appropriate HIF response depending on oxygen availability in 146 
addition to the PHD-pVHL system. 147 
 148 
3.2. Phosphorylation by PLK3 149 
Polo-like kinase 3 (PLK3), a regulator of the cellular stress response and cell cycle progression, 150 
targets HIF-1α for degradation via direct phosphorylation of two sites, S576 and S657 [50]. This 151 
phosphorylation occurs during normoxia to target HIF-1α for proteasomal degradation in a pVHL-152 
independent manner. Only one of these target sites, S576, is located within the ODD domain, while 153 
the other, S657, is immediately after the HIF-1α nuclear export signal (NES). The role of PLK3 in 154 
regulating cell survival and proliferation in vivo has been further demonstrated by the same group, 155 
via PLK3-dependent phosphorylation of PTEN to enhance PTEN protein stability [51]. More recently, 156 
evidence has been gathered suggesting that PLK3 is suppressed by both hypoxia and Ni(II) (which 157 
acts as a hypoxia mimetic by blocking PHDs) [52,53]. The latter studies proposed a signalling 158 
paradigm whereby, in normoxia, PLK3 destabilises both HIF-1α and the E3-ligase SIAH2. Among 159 
the SIAH2 targets are PLK3 and PHD1/3 [53-55]. Thus, under hypoxia, or in the presence of at least 160 
Ni(II)), SIAH2 protein levels increase and then induce ubiquitin-mediated proteasomal degradation 161 
of PLK3 as well as PHD1 and PHD3. Although USP28 appears to be capable of reversing PLK3 162 
polyubiquitination to increase its stability, USP28 levels and activity were found to be suppressed by 163 
both hypoxia and Ni(II), which would contribute to PLK3 suppression (Figure 3). While the co-164 
existence of both pVHL-dependent and -independent mechanisms for normoxia-specific HIF-1α 165 
degradation might initially appear redundant, the presence of both systems may form a contingency 166 
to ensure appropriate HIF regulation in the event of pVHL becoming functionally compromised. 167 
 168 
3.3 Phosphorylation by CDKs 169 
Not all phosphorylations of HIFs decrease their stability, some do the opposite. Cyclin-170 
dependent kinases (CDKs) belong to an important family of proteins involved in regulating and fine 171 
-tuning several stages of the cell cycle [56]. HIF-1α has been shown to act as a negative regulator of 172 
DNA replication, exerting control over cell cycle progression [57]. CDK1, a key cell cycle regulator 173 
conserved across all eukaryotes and promotes entry into the M-phase of mitosis, directly interacts 174 
with and phosphorylates HIF-1α at S668, in an oxygen-independent manner. Although this 175 
phosphorylation increased HIF's protein stability, the mechanisms appear to involve both the 176 
proteasome and/or lysosomal degradation of HIF-1α during the G1/S transition [58,59]. In addition, 177 
CDK2 positively regulates HIF-1α transactivity in cancer cells, and it was postulated that CDK2 could 178 
uncouple the transcriptional and non-transcriptional functions of HIF-1α in a manner analogous to 179 
the well-characterised mechanism involving cMYC and SKP2 [58,60]. Furthermore, CDK5, which is 180 
distinct from the other CDKs as it does not involve a cyclin subunit for catalytic activation, modifies 181 
HIF-1α at S687 and increases its stability [61]. Overall, this highlights the importance of oxygen-182 
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dependent and -independent mechanisms merging at HIF-lα to determine cellular fate during 183 
growth and division.  184 
 185 
3.4 Phosphorylation by PKA 186 
The intracellular protein kinase A (PKA), an essential kinase activated by cAMP, has also been 187 
associated with increased HIF stability. Initially, PKA was shown to be involved in the HIF-lα 188 
response to intermittent hypoxia in EAhy926 endothelial cells, yet the phosphorylation sites within 189 
HIF-1α remained unknown [62]. Later on, it was found that PKA phosphorylated 6 different sites 190 
spanning the full length of HIF-1α in vitro, with T63 and S692 phosphorylation promoting oxygen-191 
independent stabilisation and increased transcriptional activity of HIF-1α [63]. Interestingly, of these 192 
6 phosphorylation sites, S31 has recently been evidenced in a separate study, to abrogate HIF-1α-193 
dependent transcription without impacting protein stability; opening up avenues of direct 194 
transcriptional regulation of HIF by PTM and potentially delineating the consensus that HIF-α 195 
stability results in HIF transcriptional regulation [64]. A recent study identified a feedback 196 
mechanism where hypoxia activates PKA via HIF-1α mediated suppression of the PKA regulatory 197 
subunit 2B (PRKAR2B) transcription, by sequestering SP1 from the PRKAR2B promoter [65]. Overall, 198 
these aspects show that the potential of crosstalk between these key signalling pathways in altering 199 
the cellular response. 200 
 201 
3.5 Phosphorylation by pATM 202 
Following the detection of DNA damage, p53, a potent tumour suppressor transcription factor, 203 
is stabilised via phosphorylation by ataxia telangiectasia mutated protein (pATM) [66]. p53 and HIF-204 
1α display extensive crosstalk to balance survival and pro-apoptotic signalling, in response to severe 205 
hypoxia or anoxia [67,68]. pATM directly modifies HIF-1α at S696 in response to hypoxia, thereby 206 
increasing its stability as well as its transcriptional activity [69]. In contradiction to this activatory role 207 
of pATM on HIF-1α, others have found that loss of pATM positively regulates the transcription and 208 
translation of HIF-1 (α and β) proteins through oxidative stress [70]. Together, this suggests a 209 
complex interrelation between pATM and HIF-1α involving direct and indirect regulatory aspects, 210 
ranging from transcriptional control via the regulation of translation and/or protein stability. 211 
 212 
3.6 HIF-1α vs HIF-2α phosphorylation, similarities and differences 213 
Given the high sequence homology between HIF-lα and HIF-2α, it is unsurprising to see 214 
equivalent phosphorylation-dependent regulation between the two HIF-α proteins. Recruitment of 215 
the CBP/p300 co-activators to the HIF-α C-TAD requires phosphorylation of a conserved threonine 216 
within the C-TAD at T796 and T844 of HIF-1α and mouse HIF-2α (human HIF-2α T840), respectively 217 
[71]. Interestingly, this T796 phosphorylation may also abrogate the HIF-1α/FIH interaction to 218 
enhance HIF-1 transcriptional activity [72,73]. Despite unsuccessful identification of the specific 219 
kinase responsible for this phosphorylation, CKII-like kinase was suggested to play a role, yet direct 220 
evidence has not yet been obtained [71,74,75].  221 
HIF-α transcriptional activity and its interaction with HIF-1β are dependent on reaching a 222 
sufficient nuclear concentration. Nuclear localisation can be regulated by HIF-1α phosphorylation at 223 
S641/S643, within the NES motif, by p42/44 mitogen-activated protein kinase (MAPK, hereafter 224 
referred to as ERK1/2) [76,77]. This ERK-dependent phosphorylation promotes HIF-1α nuclear 225 
localisation by blocking exportin chromosomal maintenance 1 (CRM1)-dependent nuclear export. 226 
Moreover, ERK1/2 phosphorylation of HIF-1α also indirectly regulates gene-specific HIF-1α 227 
transcriptional activation and enhances protein stability. Either S641 and S643 phosphorylation 228 
constitutes a PIN1 consensus motif (pSer-Pro), whereby PIN1, a peptidyl-prolyl cis/trans isomerase 229 
overexpressed in several human cancers, induces a conformational change in HIF-1α to increase 230 
protein stability and transcriptional activity in an ERK1/2-dependent manner [78,79]. Interestingly, 231 
an inverse association has been noted between cancer and Alzheimer's Disease (AD) concerning PIN1 232 
regulation of HIF-1α [80]. While PIN1 overexpression in cancer has been correlated with increased 233 
HIF-1α stability, the inverse is suggested to occur with AD whereby PIN1 promotes HIF-1α 234 
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degradation via a GSK-3β-dependent mechanism [78,81]. Once HIF-1α localises to the nucleus, its 235 
interaction with HIF-1β can be disrupted by phosphorylation of S247 by casein kinase 1 δ (CK1δ) [82]. 236 
Much like HIF-1α, HIF-2α nuclear localisation is regulated by ERK1/2 phosphorylation at S672 [83]. 237 
Consequently, this masks the NES within HIF-2α and directly inhibits CRM1-dependent nuclear 238 
export of HIF-2α at an atypical NES. Despite in vitro findings for HIF-2α being capable of interacting 239 
with PIN1, no investigation has yet identified equivalent HIF-1/PIN1 regulation on HIF-2 [79]. 240 
Furthermore, HIF-2α nuclear localisation is also dependent on additional modification at S383 and 241 
T528 by CK1δ, which assists indirectly to the CRM1-dependent mechanism, by facilitating nuclear 242 
retention likely via binding to immobile nuclear (or chromatin) components [84].  243 
While the similarity of mechanisms regulating both HIF-α proteins is not surprising, it is the 244 
specific differences in their respective sequences that specialise them for some distinct roles. For 245 
instance, during hypoxia, HIF-1α suppresses key mismatch DNA-damage repair genes by competing 246 
with MYC for SP1 binding within target gene promoters, but, this does not occur with HIF-2α due to 247 
unique phosphorylation within its PAS-B domain on T324 by protein kinase D1 (PKD1) [85]. The 248 
T324 phosphorylation occurs within a motif requiring an obligatory upstream proline, which is not 249 
present in HIF-1α, hence abrogating SP1 binding. 250 
 251 
3.7 Beyond direct HIF protein phosphorylation; indirect kinase-dependent HIF-α regulation 252 
Kinases regulating HIF-α transcription, synthesis, or degradation by acting upstream or 253 
downstream on critical regulators of these processes were also shown to integrate different signalling 254 
pathways with the HIF response (Figure 3). Despite HIF-α transcriptional regulation not being the 255 
focus of this review, it is nevertheless important to highlight how such signalling crosstalks including 256 
JAK/STAT3 and NF-kB signalling have been associated with upregulation of HIF-1α at the 257 
transcriptional level [86-90]. Furthermore, PI3K/AKT and ERK1/2 appear to affect at least HIF-1α 258 
transcription in response to reactive oxygen species (ROS) generated by arsenite [91]. ROS involve 259 
binding of nuclear factor erythroid 2-related factor 2 (NRF2) to an antioxidant response element 260 
(ARE) located approximately 30 kilobases upstream of the HIF1A transcriptional start [91,92]. 261 
Likewise there are mechanisms downregulating HIF-α transcription. For instance, the kinase double-262 
stranded RNA–dependent protein kinase R (PKR), associated with eukaryotic initiation factor 2 263 
(eIF2), can act outside of the eIF2 pathway to impair HIF1A transcription via inhibition of the STAT3 264 
signalling [93]. The participation of mTOR in the regulation of HIF-1α protein translation was also 265 
described [94]. Further, an mTOR signalling motif (FVMVL) immediately C-terminal of the PAS-A 266 
domain in HIF-1α appeared to modulate the recruitment of CBP/p300 [95]. HIF-1α transcriptional 267 
activity has also shown evidence of positive regulation via kinases, but independent of their catalytic 268 
activity, whereby CDK8 is capable of associating with HIF-1α to induce RNA Polymerase II 269 
transcription [96]. Altogether, those findings outline the additional control, via kinase-controlled 270 
pathways, of HIF-α production. 271 
 272 
 273 
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 21 
 
 
 
 
Figure 3. The intracellular protein-dependent cell signalling for the transcriptional, translational, and 274 
phosphorylation-dependent regulation of HIF-α. Purple arrows indicate protein kinases that directly 275 
phosphorylate HIF-α. 276 
 277 
4. Acetylation 278 
Acetylation is a compelling class of modification in terms of HIF-α functional outcome, leading 279 
to diverse effects. Since establishing the canonical consensus of HIF-α stabilisation, investigations 280 
have highlighted that acetylation plays a crucial role in coordinating this fundamental response. 281 
Mouse arrest defective-1 (mARD1225) acetylation of the HIF-1α ODD domain, at K532, accelerates the 282 
HIF-1α/pVHL interaction under normoxia, contributing to HIF-1α proteasomal degradation [97]. 283 
However, given that humans do not express mARD1225 it remains unclear as to whether this 284 
regulation occurs in human cells. Some investigations have been unsuccessful in reproducing this 285 
observed increase in protein degradation when using either mARD1225 or human ARD1 286 
(hARD1/NAA10) [98,99]. Recent evidence suggests that FIH is required to directly modify 287 
hARD1/NAA10, at W38, during normoxia (utilising molecular oxygen as a cofactor) to activate its 288 
lysine acetyltransferase activity, thereby facilitating HIF-1α acetylation [100]. This FIH-mediated 289 
activation could explain the previously suggested normoxia specific regulation imposed by 290 
hARD1/NAA10. The co-activator p300 also acetylates HIF-1α, at K709, to increase protein stability 291 
under hypoxia by suppressing its polyubiquitylation [101]. This acetylation is antagonised and 292 
removed by SIRT2, which interacts directly to enhance the HIF-1α-PHD2 interaction [102]. 293 
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Acetylation has also been recognised to induce changes in HIF-α outside of the canonical pVHL-295 
mediated pathway. In that respect, HDAC4 regulates HIF-1α deacetylation, which in turn enhances 296 
HIF-1α protein stability by blocking non-pVHL-mediated proteasomal degradation [103]. 297 
Additionally, HDAC4 increases HIF-1α transactivity. Although the precise localisation of the 298 
individual lysine residues was not determined, the authors postulated that a combination of 5 lysines 299 
(K10, K11, K12, K19 and K21) within the bHLH domain is involved. In terms of the acetylation 300 
machinery modifying HIF-α, HDAC4 is not the sole regulator. Under hypoxia, the CBP/p300-301 
associated factor (PCAF) facilitates the CBP/p300 interaction with the HIF-1α CTAD via acetylation 302 
of K674 [99]. Given that K674 is conserved across other mammals containing the HIF-1α ortholog, it 303 
is likely that modification of this site plays an integral role in regulating transactivity. Interestingly, 304 
K674 acetylation can be antagonised by SIRT1, which abrogates the CBP/p300 interaction to inactivate 305 
HIF-1α. However, SIRT1 can itself be downregulated by hypoxia. SIRT1 also interacts with HIF-2α 306 
to facilitate the deacetylation of residues K385, K685 and K741 [104]. While SIRT1 downregulates 307 
HIF-1α transactivity, it does the opposite to HIF-2α leading to increased transcriptional activation.  308 
 309 
 
 
 
Figure 4. The amino acid sites of HIF-α subjected to acetylation and the acetyltransferase enzymes 310 
attributed to the relevant sites. A '?' represents an unknown regulator, not currently described in the 311 
literature. PTMs with yellow and blue backgrounds indicate activatory and inhibitory effects, 312 
respectively. 313 
 314 
5. Methylation 315 
Most-commonly methylation of proteins occurs at arginine or lysine residues. Methylation has 316 
been widely studied in conjunction with histone proteins where they regulate DNA accessibility for 317 
transcription. In addition, methylation also regulates other proteins, including HIF-α, to induce 318 
functional changes. SET7/9, a monomethyl transferase known for its role in gene activation via 319 
modification of histone H3, has been found to also interact with HIF-1α and to methylate multiple 320 
sites [105-107]. The SET7/9-mediated methylation at K391 on HIF-1α induces protein destabilisation 321 
via the canonical PHD/VHL pathway [106]. This could be antagonised by lysine-specific demethylase 322 
1 (LSD1). LSD1 is a member of the nucleosome remodelling and deacetylase (NuRD) complex. It has 323 
been proposed that the LSD1 demethylating activity suppresses PHD2-mediated hydroxylation and 324 
promotes deacetylation of HIF-1α at K532 (supposed to be acetylated by ARD1) [97,106].  325 
Other studies indicate that SET7/9 can methylate both HIF-1α and HIF-2α at the conserved sites 326 
K32 and K29 within the bHLH domains, respectively [107]. Initially, K32 HIF-1α (and K29 HIF-2α) 327 
methylation was found to induce transcriptional inhibition independent of HIF-1α protein 328 
degradation, while a later investigation reported that SET7/9 methylated HIF-1α was degraded by 329 
the 26S proteasome in a hydroxylation-independent manner [105,107]. Again, LSD1 was capable of 330 
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reversing the methylation at K32 and of stabilising HIF-1α under hypoxic conditions. In line, LSD1 331 
was then found to upregulate HIF-1α-dependent angiogenesis by increasing CBP, MTA1 and HIF-332 
1α binding to the VEGF promoter [105,106]. Interestingly, K32 resides near two residues found to be 333 
mutated in various human cancers, S28Y and R30Q, which alter the SET7/9 consensus site when 334 
mutated to prevent methylation, thus leading to increased HIF-1α stability [105]. Aside from SET7/9 335 
mono-methylation, more recently, G9a/G9a-like protein (GLP) has been recognised to both mono- 336 
and di-methylate HIF-1α at K674 [108]. This is the same site that can be acetylated by PCAF (see 337 
above), but with here an opposite effect, by inhibiting transactivation [108]. Lysine acetylation and 338 
methylation have distinct effects on the physicochemical properties of a target residue, either 339 
maintaining a residues positive charge or neutralising it, respectively, leading to distinct 340 
proteoforms. The mutual exclusivity of these lysine PTMs evidence the complex cross-regulation of 341 
HIF-1α.  342 
 343 
 
 
 
Figure 5. The amino acid sites of HIF-α methylation and the methyltransferase enzymes responsible 344 
for each site-specific modification. PTMs with yellow and blue backgrounds indicate activatory and 345 
inhibitory effects, respectively. 346 
 347 
6. SUMOylation 348 
SUMO is comparable to ubiquitin in terms of its overall molecular structure and molecular 349 
weight yet can lead to distinct changes in a given protein regulation depending on the SUMO 350 
isoforms [109]. The functional outcome of HIF-1α SUMOylation remains unclear due to controversy 351 
between investigations. The first report of HIF-1α SUMOylation suggested that modification by 352 
SUMO-1 increased HIF-1α protein stability and transactivity [110]. SUMO-1 was proposed to 353 
compete with ubiquitin for linkage at K391 and K477 within HIF-1α's SUMO consensus sequences. 354 
Contrary to this, another study evidenced that SUMOylation of K391 and K477 induces a decrease in 355 
transcriptional activity, which appeared to be independent of altering HIF-1α's half-life under 356 
hypoxia [111]. Aside from the identification and characterisation of specific SUMOylatable residues, 357 
several investigations have identified enzymes capable of initiating SUMO conjugation to HIF-1α. 358 
PIASy is an E3-ligase responsible for SUMOylating HIF-1α in two regions. One site residing within 359 
the ODD domain (between residues 331-698) and the other lying further upstream (between residues 360 
211-330) [112]. PIASy-mediated SUMOylation negatively regulated HIF-1α transactivity and protein 361 
stability and reduced epithelial cell angiogenic activity. Further, the SUMO E3 ligase Cbx4 modifies 362 
HIF-1α at K391 and K477 to enhance HIF-1's transcriptional activity [113]. While both HIF-1α and 363 
HIF-2α are targets for SUMOylation, fewer sites of modifications have been identified in HIF-2α. 364 
Despite HIF-2α containing two SUMO consensus sites, only one, K394, was found to be conjugatable 365 
by SUMO [114]. Interestingly, the enzymatic addition of SUMO-2 facilitated recognition by SUMO-366 
8265755311 17 70 15885 228 298 401 603 786
PAS-A PAS-B ODDD NTAD CTADHIF-1α
8705424961 14 67 15484 230 300 404 568 830
PAS-A PAS-B ODDD NTAD CTADHIF-2α
bHLH
bHLH
MethylationMe
SET7/9 G9a/GLP
K674K391
Me Me
K32
Me
K29
Me
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 11 of 21 
 
targeted ubiquitin ligases (pVHL and RNF4) to rapidly degrade HIF-2α under hypoxia. Furthermore, 367 
this investigation also highlighted that the SUMO-protease SENP1, which has shown action against 368 
HIF-1α, is also capable to recognise and regulate HIF-2α. 369 
 370 
7. S-Nitrosylation 371 
Not all PTMs are enzymatically driven, with one such example being S-nitrosylation. S-372 
nitrosylation is yet another PTM with conflicting views regarding the functional outcome of its 373 
modification. Initially, C800 S-nitrosylation was identified as a critical modification for CBP/p300 374 
recruitment and transcriptional activation [115]. However, a later investigation found that 375 
incorporation of the polar NO group potentially disrupted this interaction with the result that C800 376 
S-nitrosylation suppressed CBP/p300 recruitment [73]. In addition, HIF-1α stability can be 377 
upregulated through NO-mediated S-nitrosylation under normoxic conditions, at C533 (mouse 378 
sequence) in the ODD domain. The stabilisation process appeared to be independent of the VHL 379 
degradation pathway [116]. Overall, S-nitrosylation seems to regulate at least HIF-1α stability and 380 
transactivity. No data are available for HIF-2α.  381 
 382 
8. Uncharacterised PTMs 383 
8.1 Glycosylation 384 
While many classes of PTM have been discussed within this review, there are still many classes 385 
that are yet to be characterised as modifiers of HIF-α. Protein glycosylation, the addition of a sugar-386 
moiety to proteins, ranges from simple monosaccharide modifications of nuclear transcription factors 387 
to highly complex branched polysaccharide additions to cell surface receptors. While several 388 
investigations suggest a link between glycosylation and hypoxia, it is still unclear whether and how 389 
HIF-α subunits are directly involved in these processes and whether they can themselves be targeted 390 
for glycosylation [117,118].  391 
 392 
8.2 S-Glutathionylation 393 
S-glutathionylation is the addition of the tripeptide glutathione (GSH) to cysteine residues of 394 
proteins. It is often stimulated by oxidative as well as nitrosative stress, yet also occurs in unstressed 395 
cells. It is involved in various cellular processes by modulating protein functions and preventing 396 
irreversible oxidation of protein thiols. Changes in oxidised glutathione can modulate HIF signalling 397 
via S-glutathionylation of target cysteines in human oral squamous cell carcinoma cells, and in C2C12 398 
mouse myoblasts [119-121]. The latter study also identified, through a biotin switch assay and 399 
subsequent MS analysis, GSH adducts on cysteine 520 (C520) within the ODD domain of human HIF-400 
1α, which led to HIF-lα protein stabilisation [121]. Interestingly, C520 in human HIF-1α is equivalent 401 
to C533 in the mouse sequence for which that S-nitrosylation prevented HIF-1α degradation [116].  402 
 403 
8.3 Neddylation 404 
Neddylation is a process by which a ubiquitin-like protein called neural precursor cell-expressed 405 
developmentally down-regulated 8 (NEDD8), is conjugated to its target proteins. As a result of the 406 
conjugation process subcellular localisation, protein stability, and activity of targeted proteins can be 407 
modified. While there is limited knowledge about direct neddylation of HIFs, we do know that HIF-408 
1α as well as HIF-2α are capable of covalent modification by NEDD8. NEDD8 stabilised HIF-1α 409 
under both normoxia and hypoxia in VHL deficient cells, suggesting a VHL-independent process 410 
[122]. More recently it was reported that SerpinB3 (SB3), a hypoxia and HIF-2α-dependent cysteine-411 
protease inhibitor, can directly neddylate and stabilise HIF-2α, which led to an upregulation of its 412 
target genes in liver cancer cells [123]. Overall, these reports underline the role of neddylation in HIF 413 
regulation, but none of the reports has yet shown the exact sites within the HIF proteins where the 414 
neddylation occurs.  415 
 416 
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9 Conclusion 417 
While many different classes and sites of PTM have been discussed here, numerous others have 418 
been identified as part of high-throughput mass spectrometry studies and are yet to be functionally 419 
investigated. Phosphositeplus is a mass spectrometry data repository for PTM data [124]. Searching 420 
Phosphositeplus identifies in excess of 50 PTMs (spanning phosphorylation, acetylation, sumoylation 421 
and ubiquitination) that have been confidently identified under different cellular conditions between 422 
HIF-1α and HIF-2α, that lack functional characterisation. Further to this, a very recent investigation, 423 
using a combination of immunoprecipitation and mass spectrometry, discovered multiple types of 424 
PTMs (and binding partners) of HIF-1α and HIF-2α and determined their O2 dependence [64]. A total 425 
of 41 (32 novel) and 39 (34 novel) different PTMs on HIF-1α and HIF-2α, respectively, were identified, 426 
spanning 13 different types of PTM, including an array of different cysteine modifications together 427 
with non-canonical cysteine phosphorylation. All of the identified PTM sites were investigated 428 
through multiple sequence alignments of >200 vertebrate species for both HIF-1α and HIF-2α [64]. 429 
Overall, few PTM sites seem to have random variants throughout evolution, rather HIF-α PTM sites 430 
are highly conserved even in domains of large sequence variation; highlighting not only the potential 431 
functional importance of PTM but also the functional importance of HIF-α themselves. Furthermore, 432 
some sites show evolutionary variation to PTM-null/mimetic amino residues, thus either removing 433 
or full activating this signalling pathway respectively. For example Ser31 in human is present as a 434 
phospho-null Gly31 in all (80+ species) Bony fish (Osteichthyes) [64]. Thus this added level of 435 
information could be used to aid in selection of PTM sites to functionally characterise and guide 436 
biological reasoning to their function.  437 
 438 
Here, we provided an overview on how post-translational modifications are critical steps for 439 
regulating HIF-α activity and stability. Given that hypoxia plays a vital role in many 440 
pathophysiological aspects, and is a prominent micro-environmental feature in many aspects of life, 441 
it may be hypothesised that specific PTM sites that highly influence functional roles, may be a 442 
selective target for mutation in tumours/cancers as survival strategies. Surprisingly, the COSMIC 443 
database (https://cancer.sanger.ac.uk/) identifies a low mutation rate of ~1.5-2% for both HIF-1α (640 444 
mutations / 41304 sequenced HIF-α genes from patient tumours) and HIF-2α (928/39561) [125]. 445 
Specifically looking for missense mutations (resulting in amino acid changes) lowers this to <1% for 446 
both HIF-1α and HIF-2α (262/41304 and 368/39561 respectively), with the vast majority of mutations 447 
occurring only once. For comparison, p53 (TP53 gene) known to have a critical role in cancer 448 
development (has a mutation rate of ~28%, a rate >20 times that of either HIF-α protein. Pathological 449 
changes in growth factor production or driver mutations, for example in receptor tyrosine kinase 450 
pathways, may enhance modification of HIFs that could contribute to cancer cell survival or death. 451 
At this time, it is difficult, if not impossible, to predict the contribution of any given post-translational 452 
modification in the context of specific diseases as their net result may depend on tissue or cell-specific 453 
aspects which may shorten or prolong HIFs half-life in one cell or the other, respectively. 454 
 455 
To date, most data available contribute to the regulation of HIF-1α, and therefore more 456 
knowledge about the PTM landscape of HIF-2α and HIF-3α will be required to increase basic 457 
understanding of hypoxia signalling, its crosstalk with other signalling networks and improve the 458 
potential for therapeutic intervention 459 
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